Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformationZachary A. Hing(The Ohio State University), Rosa Lapalombella(The Ohio State University)Nature CommunicationsJanuary 6, 202310.1038/s41467-022-35778-1Cited by 32SaveCiteExport RISWatch citationsRelated PapersVIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia|Leukemia|2022|37Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia|Nature Communications|2021|9